NEW YORK (TheStreet) -- We hear all the time that when (fill in the blank) speaks, people listen.It is clear TheStreet's Jim Cramer fits into that category. After seeing the 33% surge in shares of TearLab> ( TEAR) only a few days after Cramer discussed the company's prospects on national television, I realize I need to listen to him more intently. While the med-tech space is not exactly new to me, for several reasons TearLab had fallen off my radar. But after Cramer's comments and the stock's immediate jump, the company's got my attention. Investors want to know if it's too late to profit. Take a look at the chart below.
As brittle as my confidence may be in buying stocks as such high levels, I don't see any alternatives on the market to compete with TearLab's system. And even if a product were to emerge today, it would be difficult to unseat the industry gains that TearLab has already won with doctors. The fact that the company was able to secure almost 400 system orders in the first quarter, growing close to 70% year over year, speaks to the trust that TearLab has established. What this also means is that management now has a problem that every company "cries" for -- fulfillment/backlog challenges, or the ability to service overwhelming demand. Along similar lines, given the company's ability to maintain/grow margins, while growing market share, I don't see what will stunt TearLab's growth or the stock's momentum. If there are any risks, it's with capital expenditure, which grew 63% in the recent quarter. while referencing TearLabs. This time I'm listening. At the time of publication, the author held no position in any of the stocks mentioned. Follow @saintssense This article was written by an independent contributor, separate from TheStreet's regular news coverage.